Company / Finance

Adaptive Biotechnologies Corporation

ADPT · NASDAQ

Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.

Latest ReportMay 14, 2026Adaptive Biotechnologies: Can clonoSEQ outrun the cash-burn clock?View report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
BiotechnologyNasdaq
Clear tags
Latest Thesis

Adaptive Biotechnologies: Can clonoSEQ outrun the cash-burn clock?

Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.

May 14, 2026Research reportSlides available
Adaptive Biotechnologies CorporationBiotechnologies: Can clonoSEQ outrun the cash-burn clock?May 14, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Adaptive Biotechnologies: Can clonoSEQ outrun the cash-burn clock?Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.NASDAQMay 14, 2026Research reportReadSlides